Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Randomized, open-label, multicenter study to investigate the efficacy and safety of umbilical
cord-derived mesenchymal stem cells (UC-MSC) for the treatment of steroid-resistant acute
graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell
transplantation (allo-HSCT), with a view to establishing an effective treatment protocol for
steroid-resistant aGVHD.
Phase:
Phase 3
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Southern Medical University, China Sun Yat-sen University Third Military Medical University